European stock markets opened higher today amid a busy earnings season – the Stoxx Europe 600 index is up 0.70%, driven mainly by the banking, technology, and healthcare sectors. Shares of Royal Philips are gaining 9.90% after raising its profitability forecast, while AstraZeneca is up 3.90% on strong oncology drug sales.
Markets are also reacting to the recently announced trade agreement between the EU and the U.S., which imposes a 15% tariff on most EU exports to the U.S., while significantly reducing tariffs on American goods. Despite the deal, Goldman Sachs has maintained its forecast of zero EPS growth in Europe for 2025, citing limited macroeconomic impact.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appDE40
The DAX is staging a solid rebound from the support zone above 24,000 points, gaining 1.10% today to reach 24,300 points. From a technical perspective, the index remains in a consolidation phase, and a breakout above the 24,600-point resistance level is needed to resume the upward trend.
Source: xStation5
Company News
Royal Philips (PHIA.NL) raised its full-year profitability outlook, now expecting an adjusted operating margin of 11.3%–11.8%, as the impact of tariffs proved less severe than anticipated. The company also reported a 1% rise in Q2 sales to €4.3 billion, recovering from its earlier May warning of a potential €300 million tariff-related hit.
AstraZeneca (AZN.SE) reported a strong second quarter, with profit before tax rising 30% to $3.13 billion and total revenue up 12% to $14.46 billion, surpassing analyst expectations. Core earnings per share reached $2.17, and EBITDA rose 22%. The company reaffirmed its 2025 outlook, expecting low double-digit growth in core EPS and high single-digit revenue growth.
Sika (SIK.CH) reported a decline in first-half profit and sales, with net income falling to 553.8 million francs and revenue down to 5.68 billion francs. Despite the drop, the Swiss chemical group expects modest full-year 2025 sales growth in local currencies and reaffirmed its 2028 targets for sustainable, profitable growth.
EssilorLuxottica (EL.FR) reported stronger-than-expected Q2 revenue, up 7.3% to €7.18 billion, beating forecasts, driven by a favorable price mix and growth in smart glasses. However, profits were pressured by US tariffs and investments in wearables, leading to a 90 basis point drop in adjusted gross profit margins for the first half.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
